The combination could allow Somavert to be used at ower/less frequent doses in acromegaly treatment (currently Somavert requires daily injection), thereby reducing treatment costs and improving patient compliance. The combination of the two drugs could also potentially open up other disease applications such as some cancers where a more significant reduction in IGF-I may be required. ANP’s Scientific Advisory Group is supportive of the concept of this combination therapy approach and its potentially clinical benefits.
I think this is the hint to the market that Pfizer is the pharmaceutical company doing the DD.
Shaping up to be a big year for ANP... looking and sounding good.
JMO, Good Luck!
ANP Price at posting:
19.0¢ Sentiment: LT Buy Disclosure: Held
